Skip to content
Clinical Trials – home
Research site

Haematologie und Onkologie Muenchen-Pasing MVZ GmbH

Germany Baeckerstrasse 4, Pasing-Obermenzing, 81241 Munich, Germany

  • 2 trials recruiting
  • Waldenstrom's macroglobulinaemia · Hormone receptor positive breast cancer · Breast cancer female
  • Adult patients

About Specializations

Haematologie und Onkologie Muenchen-Pasing MVZ GmbH in Munich, Germany specialises in clinical trials of conditions such as Waldenstrom's macroglobulinaemia, Hormone receptor positive breast cancer, Breast cancer female, Hormone receptor positive HER2 negative breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Waldenström’s Macroglobulinemia

The medical center is at the forefront of research in Waldenström’s Macroglobulinemia, focusing on innovative therapeutic combinations to enhance patient outcomes.

  • Bortezomib, Rituximab, Ibrutinib (B-RI) Therapy
  • Carfilzomib and Ibrutinib Combination
  • Venetoclax and Rituximab Efficacy

These studies aim to improve progression-free survival rates and explore the efficacy of novel drug combinations, offering new hope for patients with this rare condition.

Multiple Myeloma

In the field of Multiple Myeloma, the center is pioneering research to evaluate the effectiveness of advanced drug regimens in relapsed or refractory cases.

  • Mezigdomide, Carfilzomib, and Dexamethasone Combination

By comparing progression-free survival rates, the center aims to establish more effective treatment protocols for patients with challenging disease profiles.

Chronic Myeloid Leukemia

Research in Chronic Myeloid Leukemia is focused on assessing the tolerability and efficacy of novel oral therapies for newly diagnosed patients.

  • Asciminib vs. Nilotinib

The goal is to optimize treatment regimens by minimizing adverse events and improving patient adherence to therapy.

Chronic Lymphocytic Leukemia

The center is advancing the understanding of Chronic Lymphocytic Leukemia through studies on the safety and tolerability of targeted monotherapies.

  • Acalabrutinib Monotherapy

This research is crucial for developing safer, more effective treatment options for both treatment-naive and relapsed/refractory patients.

Follicular Lymphoma

In the realm of Follicular Lymphoma, the center is exploring the benefits of combining novel immunotherapies with established treatments.

  • Mosunetuzumab and Lenalidomide Combination

These efforts aim to enhance progression-free survival and offer new therapeutic avenues for patients with previously untreated conditions.

Myelodysplastic Syndromes

Research on Myelodysplastic Syndromes is focused on improving hematologic outcomes for patients with lower-risk profiles.

  • Luspatercept for Anemia Treatment

The center's work seeks to provide transfusion independence and improve quality of life for patients with anemia due to MDS.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Baeckerstrasse 4, Pasing-Obermenzing81241 MunichGermany
Recruiting now
2 trials
Conditions studied
8

More sites in MunichGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

9 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Ulm AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut fuer Frauengesundheit GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Universitaet Leipzig
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universitaetsklinikum Ulm AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Ulm AöR
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.